TGTX
TG Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.95B
P/E Ratio
13.59
EPS
$2.86
Beta
1.68
52W High
$44.65
52W Low
$25.28
50-Day MA
$35.41
200-Day MA
$32.26
Dividend Yield
—
Profit Margin
65.90%
Forward P/E
29.85
PEG Ratio
1.61
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $700.35M |
| Gross Profit (TTM) | $581.67M |
| EBITDA | $149.58M |
| Operating Margin | 17.00% |
| Return on Equity | 112.60% |
| Return on Assets | 8.55% |
| Revenue/Share (TTM) | $4.87 |
| Book Value | $4.52 |
| Price-to-Book | 10.20 |
| Price-to-Sales (TTM) | 8.50 |
| EV/Revenue | 8.83 |
| EV/EBITDA | 41.20 |
| Quarterly Earnings Growth (YoY) | 300.00% |
| Quarterly Revenue Growth (YoY) | 69.60% |
| Shares Outstanding | $153.08M |
| Float | $135.10M |
| % Insiders | 7.47% |
| % Institutions | 70.23% |
Historical Volatility
HV 10-Day
27.22%
HV 20-Day
65.48%
HV 30-Day
59.01%
HV 60-Day
52.90%
HV Rank
78.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($48.00 target)
1
Strong Buy6
Buy1
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026